Cary Street Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cary Street Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,500	Closed	-$198K	–	941
2025 Q1	$198K	Buy	+1,500	New	+$187K	0.01%	751

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cary Street Partners's ITCI Position: Q2 2025 in Review

Cary Street Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,500 shares — an estimated $198K sold.

Cary Street Partners first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $198K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Cary Street Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Cary Street Partners sold 1,500 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $198K.
Cary Street Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Cary Street Partners's Intra-Cellular Therapies Inc. position peaked at $198K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Cary Street Partners's 13F filing for Q2 2025, filed 13 Aug 2025.